profit from every $100 of sales.
$0$100
Phibro Animal Health
$35.97+1.44% today
-19.5% in 1 year
1-year low $28.521-year high $59.58
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay $30.26 for every $1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Phibro Animal Health sold, what it kept, and what it did with the cash.
Sales went from $942 million in 2022 to $1.30 billion in 2025, with $48.3 million of profit last year.
SalesProfit
Phibro Animal Health handed back 46% of the cash it generated last year.
$19M
Free cash flow 2025$42M
Bought back its own shares–
Paid as dividends$19M
Cash vs. debt$68M vs. $762M
Phibro Animal Health vs. similar companies
Phibro Animal Health grows the fastest of these 5 and is priced in the middle for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Phibro Animal Health | 30.3× · Expensive | ||
 Merck KGaA | 24.9× · Fair price | ||
 Takeda Pharmaceutical | 102.5× · Very expensive | ||
 Galderma Group | 86.9× · Very expensive | ||
 Teva Pharmaceutical Industries | 36.8× · Expensive |
AI analysis
An AI analyst reads Phibro Animal Health's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 942 | 978 | 1,018 | 1,296 | |
| 285 | 298 | 313 | 400 | |
| 79 | 72 | 53 | 110 | |
| 117 | 106 | 69 | 147 | |
| 49 | 33 | 2 | 48 | |
| 1.21 | 0.81 | 0.06 | 1.19 | |
| 30.3% | 30.5% | 30.8% | 30.9% | |
| 8.4% | 7.3% | 5.2% | 8.5% | |
| 5.2% | 3.3% | 0.2% | 3.7% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 932 | 971 | 982 | 1,361 |
| Cash | 74 | 41 | 71 | 68 |
| Total debt | 470 | 510 | 525 | 762 |
| Total liabilities | 669 | 689 | 726 | 1,075 |
| 262 | 283 | 257 | 286 | |
| 41 | 41 | 41 | 41 | |
| 9.1% | 7.2% | 3.3% | 7.6% | |
| 18.7% | 11.5% | 0.9% | 16.9% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 32 | 13 | 88 | 80 | |
| 37 | 52 | 41 | 38 | |
| -5 | -38 | 46 | 42 | |
| Dividends paid | 19 | 19 | 19 | 19 |
| – | – | – | – | |
| 0 | 0 | 0 | 1 |
Valuation
- 30.3×
- 11.9×
- –
- 4.1×
- 1.1×
- 34.9×
- 14.7×
- 2.9%
- 3.3%
- 1.3%
Profitability
- 30.9%
- 8.5%
- 3.7%
- 15.7%
- 11.2%
- 4.8%
- 29.5%
- 6.6%
- 15.5%
- –
Growth
- +11.2%
- −0.6%
- −9.8%
- +0.0%
- +0.0%
Financial health
- 3.1×
- 2.18
- 54.5%
- 3.9×
- 3.17
- 1.26
- 1.04
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 26%of 964
Bottom 43%of 898
Bottom 45%of 651
Top 48%of 911
Top 39%of 991
What analysts expect
- Average price target
- $49.00
- Range
- $49.00 – $49.00
- 1 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 6, 2026 | 0.76 | 0.72 | +5.6% |
| Feb 4, 2026 | 0.87 | 0.69 | +26.1% |
| Nov 5, 2025 | 0.73 | 0.59 | +23.7% |
| Aug 27, 2025 | 0.57 | 0.52 | +9.6% |
| May 7, 2025 | 0.63 | 0.52 | +21.2% |
| Feb 5, 2025 | 0.54 | 0.40 | +35.0% |
| Nov 7, 2024 | 0.35 | 0.25 | +40.0% |
| Aug 28, 2024 | 0.41 | 0.34 | +20.6% |
1.3%of the share price, paid each year
On $1,000 invested$13a year at today's yield, before tax
+0.0%2020 to 2025
Raised–not every year
Paid per share, each year
$0.40 in 2015 → $0.48 in 2025
How safe it looks
40.3% of its profit
Room to growStretchedMore than it earns: 46.5%
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
35No pass
Benjamin Graham
43No pass
Philip Fisher
32No pass
Peter Lynch
20No pass
Joel Greenblatt
24No pass
Charlie Munger
27No pass
Terry Smith
28No pass
Questions about Phibro Animal Health
Is Phibro Animal Health a good stock to buy?
A business with weak numbers, but the price is high. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Phibro Animal Health AI analysis
What does Phibro Animal Health do?
Phibro Animal Health Corporation develops, manufactures, and supplies a range of animal health and mineral nutrition products for livestock primarily in the United States. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. It is in Drug Manufacturers - Specialty & Generic.
Does Phibro Animal Health pay a dividend?
Yes. At today's price the dividend is 1.3% a year, about 40% of its yearly profit. In 2025 it paid out $19.4 million in dividends.
Is Phibro Animal Health stock halal?
No. Phibro Animal Health does not pass our halal screen: its debt is 52% of its market value, at or above the 33% limit. How we check
How has Phibro Animal Health stock done over the past year?
Down 19.5% over the past twelve months, to $35.97. It traded between $28.52 and $59.58 and is 39.6% below its high.
Who are Phibro Animal Health's competitors?
The largest listed companies in the same industry are Merck KGaA, Takeda Pharmaceutical, Galderma Group and Teva Pharmaceutical Industries. The peers table on this page compares their profit, growth and price with Phibro Animal Health's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.